JAK Janus Kinase

Cat.No.	Name	Information
M3030	S-Ruxolitinib	S-Ruxolitinib is the chirality of INCB018424, which is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus JAK3.
M1820	Tofacitinib	Tofacitinib (formerly tasocitinib, CP-690550) is a novel Janus Kinase 3 (JAK-3) kinase inhibitor with an IC50 value estimated at 0.2 μM.
M1660	AZ 960	AZ 960 is a novel and specific inhibitor of the JAK2 kinase with a Ki of 0.45nM in vitro.
M1646	AG490	AG490 (Tyrphostin AG490) is a selective inhibitor of EGF receptor tyrosine kinase (IC50 values are 2 and 13.5 μM for EGFR and ErbB2 respectively).
M1733	TG101348	TG101348 is a selective small-molecule Janus kinase 2 (JAK2) inhibitor with IC50 of 3 nM.
M1787	INCB18424	Ruxolitinib (INCB018424) is a first-in-class, potent, selective JAK1/2 inhibitor with an IC50 of 3.3 nM/2.8 nM. It is more than 130-fold more selective for JAK1, JAK2, and JAK3 than JAK3. It can be used in studies related to pemphigus, myelofibrosis and vitiligo.
M5944	Ruxolitinib phosphate	Ruxolitinib phosphate(INCB018424 phosphate) is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus JAK3.
M3616	Tofacitinib citrate	Tofacitinib (CP-690550) Citrate is a novel inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent against JAK2 and JAK1.
M2346	Filgotinib	Filgotinib (GLPG0634) is the first selective inhibitor of JAK1 and JAK2 with IC50 of 10nM and 28nM respectively.
M2044	AZD1480	AZD1480 is a novel small-molecule inhibitor of JAK1/2 with IC50 of 1.3 nM and 0.26 nM, respectively.
M9142	FLLL32	FLLL32 is a potent JAK2/STAT3 inhibitor with IC50 of <5 μM.
M9035	WHI-P97	WHI-P97 is a JAK3 inhibitor with an estimated Ki value of 0.09 microM from modeling studies and a measured IC50 value of 2.5 microM in EGFR kinase inhibition assays.
M8996	SAR-20347	SAR-20347 is a potent dual inhibitor of JAK1 and TYK2 with IC50 values of 23 and 0.6 nM, respectively.
M8876	Itacitinib	Itacitinib (INCB039110) is a potent, selective JAK1 inhibitor with an IC50 value of 2 nM for human JAK1. It has oral bioactivity and potential anti-tumor activity.
M8090	PF-04965842	Abrocitinib is an orally active and selective JAK1 inhibitor with an IC50 value of 29 nM. Abrocitinib reversibly inhibits JAK1 kinase by blocking its ATP-binding site. Abrocitinib (PF-04965842) inhibited TYK2 activity (IC50, 1.253 μM) and phosphorylation of STAT1, STAT3, and STAT5 after stimulation. It can be used in the study of autoimmune diseases.
M7551	Solcitinib	Solcitinib is an oral, competitive, potent, and selective JAK1 inhibitor with an IC50 value of 9.8 nM, which is 11,55, and 23 times more selective than JAK2, JAK3, and TYK2. Solcitinib can be used in studies of psoriasis.
M6315	1,2,3,4,5,6-Hexabromocyclohexane	1,2,3,4,5,6-Hexabromocyclohexane is a inhibits JAK2 autophosphorylation.
M6297	Upadacitinib	Upadacitinib (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC50=43 nM). Upadacitinib (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib (ABT-494) can be used for several autoimmune disorders research.
M5827	Oclacitinib maleate	Oclacitinib is a novel inhibitor of JAK family members with IC50 ranging from 10 to 99 nM and JAK1-dependent cytokines with IC50 ranging from 36 to 249 nM, which did not inhibit a panel of 38 non-JAK kinases.
M5315	Baricitinib phosphate	Baricitinib phosphate(INCB 028050; LY 3009104) is a selective JAK1 and JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM, ~70 and ~10-fold selective versus JAK3 and Tyk2, no inhibition to c-Met and Chk2.
M5028	JANEX-1	Janex-1 is a cell-permeable, reversible, potent, ATP-competitive, and specific inhibitor of JAK3 (IC50 = 78 μM); has no effect on JAK1, JAK2, or Zap/Syk or SRC tyrosine kinases.
M4980	Decernotinib	Decernotinib is a potent and selective Janus kinase 3 (JAK3) inhibitor with Ki of 2.5 nM; IC50 is 50-170 nM in cellular assays.
M4912	GLPG0634 analogue	GLPG0634 analogue is a selective JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively.
M4870	Cerdulatinib	Cerdulatinib (PRT-062070, PRT2070) is an orally active multi-target tyrosine kinase inhibitor with IC50s of JAK1/JAK2/JAK3/TYK2 and Syk 12 nM/6 nM/8 nM/0.5 nM and 32 nM, respectively. It was also able to inhibit the other 19 kinases tested, all with IC50 below 200 nM.
M4670	Curculigoside	Curculigoside is the main saponin in C. orchioide, which has significant antioxidant, anti-osteoporosis, anti-depression and neuroprotective effects. By regulating the JAK/STAT/NF-κB signaling pathway, it showed significant anti-arthritis effects in vivo and in vitro.
M4572	Limonin	Limonin is a potent inhibitor of CYP3A4 with an IC50 of 6.2 μM. Limonin inhibits HIV-1 with an EC50 of 60.0 μM. Limonin induces human colon adenocarcinoma cells apoptosis with an IC50 of 54.74 μM. Limonin, a triterpenoid rich in citrus fruits, has antiviral and anti-tumor activities.
M3801	TCS 21311	TCS 21311 is a potent JAK3 inhibitor with IC50 of 8 nM.
M3737	Pyridone 6	Pyridone 6 is a potent, reversible, cell-permeable, and ATP-competitive inhibitor of JAK1 (IC50 = 15 nM for murine JAK1), JAK2 (IC50 = 1 nM), JAK3 (Ki = 5 nM), and Tyk 2 (IC50 = 1 nM) (Janus protein tyrosine kinases).
M3735	JAK2 Inhibitor V	JAK2 Inhibitor V, Z3 is a novel specific inhibitor of Jak2 which inhibits Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner but was not cytotoxic to cells at concentrations that inhibited kinase activity.
M3535	Gandotinib	Gandotinib (LY2784544) is a potent JAK2 inhibitor with IC50 of 3 nM, effective in JAK2V617F, 8- and 20-fold selective versus JAK1 and JAK3.

By Signaling Pathways

By Product Type

Signaling Pathways

JAK Janus Kinase

Get to Know Us

Customer Support

Resources

Contact Us